Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. (PACT-01)

  • End date
    Sep 20, 2026
  • participants needed
  • sponsor
    Institut Curie
Updated on 4 October 2022
cancer treatment
cancer chemotherapy
lung carcinoma


Sequential comparative prospective interventional study evaluating the impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care. Comparison between a first period, period (A), of care as usual and a second period, period (B), of systematic and iterative use of a device for optimizing the decision to continue an anti-cancer treatment.


We propose to study the optimization of this decision process in an advanced Non-Small-Cell Lung Carcinoma (NSCLC) population, with a Performance Status (PS) ≥ 2 (median survival of approximately 3 months) piloting iteratively (before each decision to continue treatment) a process consisting of an evaluation framework (30 items to be answered by the oncologist with the patient), consolidating:

  1. clinical parameters;
  2. doctors' expectations regarding the continuation of anticancer treatment;
  3. patient expectations and preferences;
  4. the possibility of referring the patient to a supportive care specialist and strengthening home care.

The process triggers a dialogue between the patient and the oncologist, based on facts and seeks objectivity, ultimately allowing a shared decision.

In this prospective comparative study, the rate of systemic oncological treatment during the last month of life will be measured consecutively, over a period of usual management, followed by a period of systematic application of a process of optimization of the medical decision.

Condition Carcinoma, Non-Small-Cell Lung, Advanced Cancer
Treatment Usual Care, Optimization of the medical decision
Clinical Study IdentifierNCT04823377
SponsorInstitut Curie
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Histologically or cytologically proven non-small-cell lung carcinoma (NSCLC) including NSCLC with oncogene addiction
Stage IV or IIB/IIIC non irradiable (8th classification TNM, UICC 2015)
ECOG Performance Status ≥ 2
Patient having completed at least one line of chemotherapy in the context of metastatic disease (or in the context of locoregional disease if the last chemotherapy was less than 6 months ago)
Age ≥ 18
Written informed consent
Patient capable, according to the investigator, to comply with the requirements of the study

Exclusion Criteria

Small Cell Lung Cancer (including mixed forms)
Patient with NSCLC for whom a decision has already been made to permanently discontinue all systemic cancer treatment
Impossible follow up for geographical, social or psychological reason
Inability to answer a questionnaire (language or neurological barrier)
Patient under guardianship
Patient being treated in a therapeutic trial
Patient not covered by social security. -
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note